Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

MELBOURNE, AUSTRALIA 28 April 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray deliver...read more

Arovella Therapeutics - Services Agreement with Q-Gen for CAR19-iNKT manufacture (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers, is pleased to announce that it has agr...read more

Arovella Therapeutics - Anagrelide patent for the United States (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers and a leader in oro-mucosal drug delive...read more

Arovella Therapeutics - Appendix 4D and Half Year Report (ASX:ALA)

To view the report, download the attached PDF.

Arovella Therapeutics - Arovella SPP Closed early over subscribed (ASX:ALA)

-- Share Purchase Plan inundated with shareholder demand with over $2.5 million in subscriptions already received. -- Offer increased to $2 million and close early and subscriptions already receive...read more

Arovella Therapeutics - Investor Presentation (ASX:ALA)

To view the presentation, download the attached PDF.

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

PERTH, AUSTRALIA 31 January 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery ...read more

Arovella Therapeutics Completes $4.57M Placement & Launches $1.5M SPP (ASX:ALA)

Firm commitments received for $4.57 million Placement to new and existing institutional and sophisticated investors at $0.038 per share The Placement includes cornerstone participation by Merchan...read more

Arovella Therapeutics - SPP Offer Booklet (ASX:ALA)

On behalf of the board of Arovella Therapeutics Limited ACN 090 987 250 (ASX: ALA) (ALA or Company), we are pleased to offer you the opportunity to purchase up to $30,000 in additional shares in ALA...read more

Arovella Therapeutics - Trading Halt (ASX:ALA)

The securities of Arovella Therapeutics Limited (‘ALA’) will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more

Arovella Therapeutics - AGM FY21 Presentation (ASX:ALA)

To view the presentation, download the attached PDF.

Arovella Therapeutics licences novel monoclonal antibody from MD Anderson (ASX:ALA)

Arovella has acquired from MD Anderson an exclusive global licence to the patent rights for a monoclonal antibody (mAb) that targets a DKK1 peptide The technology can be used as a Chimeric Antige...read more

Arovella Therapeutics - R&D Tax Incentive refund received (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and con...read more

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

SUDA Pharmaceuticals - Chile Ministry of Health Approval Granted for ZolpiMist (ASX:ALA)

Chile approval achieved for SUDA’s ZolpiMist® This approval enables ZolpiMist to be marketed in Chile by SUDA’s partner, Teva Pharmaceuticals This is the first of Teva’s t...read more

Viewing: 1 - 15 of 101 Previous | Next